Funding for this research was provided by:
Foundation for the National Institutes of Health (UL1TR001453-01, K23HL150341, K24AI106822)
Received: 20 October 2021
Accepted: 12 March 2022
First Online: 26 March 2022
: This project was approved by the Institutional Review Board at the University of Massachusetts Chan Medical School.
: Not applicable.
: JG provides consulting services for Syneos Health. WP received grants and personal fees from Genentech/Novartis, Regeneron/Sanofi, and GlaxoSmithKline; provided consulting services and clinical trial support for asthma research for Genentech/Novartis, Regeneron/Sanofi, and GlaxoSmithKline; and provided clinical trial support for asthma research for Merck. NB served on advisory boards for Sage Therapeutics or their agents, Mathematica Policy Research; is a consultant for the Gerson Lehrman Group, Sage Therapeutics, or their agents and Ovia Health; received honoraria for speaking engagements from Sage Therapeutics or its agents and Miller Medical Communications; is a speaker and member of Perinatal Depression Steering Committee for Medscape; is a Medical Director of Massachusetts Child Psychiatry Access Program for Moms (MCPAP for Moms); and is an Executive Director of Lifeline for Moms. LBG received product donation from Thayer Medical Corporation. For the remaining authors, no conflicts were declared.